South Carolina is currently home to 1173 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Charleston, Greenville, Spartanburg and Columbia. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650
Recruiting
The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypotheses are that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per P... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Ralph H. Johnson VA Health Care System (RHJVAHCS)-Urology ( Site 0083), Charleston, South Carolina
Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Register for Updates
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease
NCT06088979
Recruiting
Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight weeks to TED patients who are in the active inflammatory phase of disease.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/14/2025
Locations: Headlands Research - TMA - Site 840-132, Myrtle Beach, South Carolina
Conditions: Thyroid Eye Disease
Register for Updates
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
NCT06079879
Recruiting
This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate response to or are intolerant of hydroxyurea. The primary study hypothesis is that bomedemstat is superior to the best available therapy with respect to durable clinicohematologic response (DCHR).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Medical University of South Carolina-Hollings Cancer Center ( Site 3426), Charleston, South Carolina
Conditions: Essential Thrombocythemia
Register for Updates
Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®
NCT05900050
Recruiting
A Phase 2, multi-center, randomized, controlled, open-label study to evaluate the effects of the intraperitoneal, liposomal formulation VS-01 in patients with an acute episode of hepatic and/or extrahepatic organ dysfunctions and failures in the presence of liver cirrhosis (Acute-on-Chronic Liver Failure, ACLF) and accumulation of fluid in the abdominal cavity (ascites)
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
08/14/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Acute-On-Chronic Liver Failure, Ascites
Register for Updates
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
NCT05754957
Recruiting
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular \[CV\] death, myocardial infarction \[MI\], and ischemic stroke).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: AnMed Health, Anderson, South Carolina
Conditions: Acute Coronary Syndrome
Register for Updates
A Retrospective Assessment of OviTex PRS (OviTex)
NCT05736848
Recruiting
The objective of this retrospective-prospective, observational study is to evaluate the safety profile overall and within two device types of OviTex PRS in previous pre-pectoral or sub-pectoral implant-based breast reconstructions.
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
08/14/2025
Locations: Plastic Surgery Consultants, Columbia, South Carolina
Conditions: Reconstructive Surgical Procedures
Register for Updates
Antibiotic Cement Bead Pouch Versus Negative Pressure Wound Therapy
NCT05615844
Recruiting
The Beads vs Vac trial is a multi-centre randomized controlled trial of 312 participants with a severe open tibia fracture requiring multiple irrigation and debridement surgeries. Eligible participants will be randomized to receive either an antibiotic bead pouch or negative pressure wound therapy (NPWT) for their temporary open fracture wound management. Outcomes will be assessed at 6 weeks, 3 months, and 6 months post-surgery. The primary outcome will be a composite outcome to evaluate clinica... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Prisma Health, Greenville, South Carolina
Conditions: Open tíbia Fracture
Register for Updates
T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer
NCT05586360
Recruiting
This study will evaluate whether simvastatin reduces intraprostatic immunosuppressive microenvironment through YAP-mediated T-reg dysfunction, and increases intraprostatic anti-tumor immune response in men recently diagnosed with localized prostate cancer electing to receive prostatectomy for their care. Half the men will be randomized to receive statins for 8 weeks prior to their surgery, while the other half will receive standard of care.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina
Conditions: Prostate Cancer
Register for Updates
Intravesical BCG vs GEMDOCE in NMIBC
NCT05538663
Recruiting
The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a non-inferior event-free survival (EFS) compared to standard treatment with intravesical BCG. The purpose of this study is to test whether Gemcitabine + Docetaxel is a better or worse treatment than the usual BCG therapy approach. The primary objective of this study is to determine the event free survival (EFS) of BCG-naïve high gr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: AnMed Health Cancer Center, Anderson, South Carolina
Conditions: Non-muscle-invasive Bladder Cancer
Register for Updates
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
NCT05489887
Recruiting
This is a prospective, multicenter clinical trial in subjects with newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of administering naxitamab with standard induction therapy. The initial chemotherapy will include 5 cycles of multi-agent chemotherapy. Naxitamab will be added to all 5 Induction cycles. We hypothesize that the addition of anti-GD2 therapy to induction chemotherapy will result in improved end of induction responses and improved survival.
Gender:
ALL
Ages:
Between 12 months and 21 years
Trial Updated:
08/14/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: High-risk Neuroblastoma
Register for Updates
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
NCT05316155
Recruiting
The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) and evaluate preliminary clinical efficacy. Part 3 (dose expansion) will confirm safety and preliminary clinical activity at the RP2D. Part 4 (RP2D expansion) will assess the overall complete response (CR) in participants with intermediate-risk-non-muscle invasive bladder cancer (IR-NMIBC; means the cancer cells are only in the bladder's inner lining).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Carolina Urologic Research Center, Myrtle Beach, South Carolina
Conditions: Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor
Register for Updates
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05156281
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/14/2025
Locations: Medical Uni of South Carolina, Charleston, South Carolina
Conditions: Relapsing Multiple Sclerosis
Register for Updates